Special Drug Use Surveillance of Entresto Tablets (Hypertension, CLCZ696A1402): ENLIGHT
Special Drug Use Surveillance of Entresto Tablets (Hypertension, CLCZ696A1402): ENLIGHT
This is a single arm, multicenter, observational study to evaluate the safety and efficacy of Entresto Tablets during the first 52 weeks of treatment in Japanese patients with hypertension.
This study is a special drug use surveillance to collect information on the safety specifications under the actual clinical practice of Entresto Tablets in patients with hypertension in Japan to confirm the occurrence and timing of onset of events related to the safety specifications and investigate their risk factors.
Inclusion Criteria:
Exclusion Criteria:
Patients who have received a formulation containing the same ingredient as Entresto (including investigational product or post-marketing clinical study drug)
The following patients for whom administration of Entresto is contraindicated in the package insert:
Patients with a history or complication of cardiac failure
Patients who have been hospitalized at the start of treatment with Entresto
Kasuya Gun, Fukuoka 811-2202, Japan
Aiko-gun, Kanagawa 243-0301, Japan
Minoo, Osaka 562-0046, Japan
Kishima-gun, Saga-ken 849-1203, Japan
Edogawa-ku, Tokyo 134-0081, Japan
Koto-ku, Tokyo 135-0003, Japan
Setagaya-ku, Tokyo 157-0066, Japan
Toshima-ku, Tokyo 171-0014, Japan